Why Moderna Stock Zoomed Higher on Wednesday
Moderna (NASDAQ: MRNA) closed nearly 6.5% higher on Wednesday thanks to the results of an early-stage clinical study of its coronavirus candidate on older patients. In the study, mRNA-1273 was found to produce the neutralizing antibodies that should immunize the body against the coronavirus. Moderna is considered by many pundits and analysts to be the leader in the race to develop a coronavirus vaccine, and this latest scrap of news will enhance its standing.
